Joshua Ooi
A/Prof. Ooi is Head of the Treg Therapies Group based at the Monash Health Translation Precinct, Monash University. The vision of his group is to translate their high-profile experimental work on regulatory T cells (Tregs) into clinical treatments for patients with autoimmune diseases. During his PhD and post-doctoral training, he demonstrated the importance of antigen-specific autoreactive T cells in causing autoimmune nephritis. He published his work in the prestigious journals PNAS, 2012; and Nat Commun, 2019; as well as >20 times in the top two nephrology journals JASN and Kidney Int. Importantly, he published a 1st author landmark paper in Nature, 2017, showing that targeted Tregs were key protectors of autoimmune disease. He has received numerous prizes for these works including the international Mosaic of Autoimmunity Award, Best Science Awards from both the Australian Immunology and Nephrology societies and, more recently, the Victoria Prize for Science and Innovation.
Abstracts this author is presenting: